Marlene Camacho-Rivera, MS, MPH, ScD, on Hispanic Trusted Cancer Information Resources

Video

The expert from the CUNY School of Medicine spoke about a recent study which indicated that Hispanic adults trust a wide variety of health information sources, suggesting the need for targeted information.

Findings from a study published in Cancer Epidemiology, Biomarkers & Prevention indicated that Hispanic adults trust a wide variety of health information sources, suggesting that information tailored to specific ethnic subgroups or various age groups could be valuable.

Altogether, the results presented in the study highlighted the importance in understanding the sources of information that are most trusted within the Hispanic population in order to properly reach the intended audience.

In an interview with CancerNetwork®, Marlene Camacho-Rivera, MS, MPH, ScD, assistant medical professor in the Department of Community Health and Social Medicine at the CUNY School of Medicine, explained that, ideally, healthcare providers, community health workers, and lay health advisers would help Hispanic individuals in identifying the most accurate information from the growing number of available sources.

“We are hoping that our study will be able to provide implications both to future public health researchers, cancer researchers, and healthcare professionals and those who are focused on designing cancer prevention either interventions or programs to really encourage scientists and practitioners to be able to think about how we design and disseminate culturally tailored information that is accessible and also trustworthy to the target populations that we’re hoping to be able to reach,” Camacho-Rivera said.

This segment comes from the CancerNetwork® portion of the MJH Life Sciences National Broadcast, airing daily on all MJH Life Sciences channels.

Reference:

Camacho-Rivera M, Gonzalez CJ, Morency JA, Blake KD, Calixte R. Heterogeneity in Trust of Cancer Information Among Hispanic Adults in the United States: An Analysis of the Health Information National Trends Survey. Cancer Epidemiol Biomarkers Prev. doi:10.1158/1055-9965.EPI-19-1375.

Recent Videos
Based on its mechanism of action, anito-cel may cause fewer instances of cytokine release syndrome and delayed toxicities vs other therapies.
2 experts are featured in this series.
Once a patient-specific dose is determined, an all-oral combination of revumenib plus decitabine/cedazuridine and venetoclax may be “very good” in AML.
Patients with lung cancer who achieve a complete response with neoadjuvant therapy may not experience additional benefit with adjuvant immunotherapy.
Numerous trials have displayed the evolution of EGFR inhibition alone or with chemotherapy/radiation in the EGFR-mutated lung cancer space.
2 experts are featured in this series.
Although high grade adverse effects are infrequent among patients undergoing treatment for SCLC, CRS and ICANS may occur in higher frequencies.
Two experts are featured in this series.
Related Content